ARTA
MTNB icon

A.R.T. Advisors’s Matinas BioPharma MTNB Stock Holding History

A.R.T. Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18
Closed -$10K – 201
2020
Q2 		$10K Buy
+18
New +$10.4K 0.02% 274
2019
Q3 		– Sell
-21
Closed -$14K – 1617
2019
Q2 		$14K Buy
+21
New +$15.1K ﹤0.01% 1304

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

A.R.T. Advisors's MTNB Position: Q3 2020 in Review

A.R.T. Advisors sold out of Matinas BioPharma (MTNB) in Q3 2020, closing a stake of 18 shares — an estimated $10K sold.

A.R.T. Advisors first reported a position in MTNB in Q2 2019 and held it in 2 quarters. The position peaked at $14K in Q2 2019. 58 funds tracked by Wall St. Rank hold MTNB as of Q3 2020.

  • A.R.T. Advisors reported no remaining Matinas BioPharma position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 18 Matinas BioPharma shares in Q3 2020, an estimated $10K.
  • A.R.T. Advisors first reported a position in Matinas BioPharma in Q2 2019 and held it in 2 quarters.
  • A.R.T. Advisors's Matinas BioPharma position peaked at $14K in Q2 2019.
  • 58 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.